Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-label Phase 1 Trial of the Safety and Efficacy of Daily Subcutaneous SPL-108 Injections When Used In Combination With Paclitaxel In Patients With Platinum-resistant, CD44+, Advanced Ovarian Epithelial Cancer

NCT03078400 is registered in ClinicalTrials.gov with Splash Pharmaceuticals, Inc. as lead sponsor.

NCT NCT03078400
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03078400 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-label Phase 1 Trial of the Safety and Efficacy of Daily Subcutaneous SPL-108 Injections When Used In Combination With Paclitaxel In Patients With Platinum-resistant, CD44+, Advanced Ovarian Epithelial Cancer
Lead sponsor
Splash Pharmaceuticals, Inc.
Phase
Phase 1
Overall status
Unknown status
Start date
March 10, 2017
Completion date
June 30, 2020
Enrollment
14 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

ovarian epithelial cancer